(ASTH) Astrana Health - Ratings and Ratios
Healthcare Services, Medical Clinics, Telehealth Visits
ASTH EPS (Earnings per Share)
ASTH Revenue
Description: ASTH Astrana Health
Astrana Health Inc (NASDAQ:ASTH) is a US-based healthcare services company. As a player in the healthcare services sub-industry, Astrana operates in a sector driven by demographic trends, regulatory changes, and the quest for cost-effective care delivery.
The companys financial performance is a critical aspect of its overall health. Return on Equity (RoE) stands at 4.93%, indicating a relatively modest return for shareholders. The Price-to-Earnings (P/E) ratio is 29.56, suggesting that investors are willing to pay a premium for Astranas earnings, potentially due to growth expectations. The forward P/E ratio is lower at 23.04, implying anticipated earnings growth.
To assess Astranas potential, key economic drivers and KPIs to watch include revenue growth, patient acquisition and retention rates, and operating margin expansion. The companys ability to navigate the complex healthcare landscape, adapt to regulatory changes, and deliver cost-effective services will be crucial. Metrics such as same-store growth, patient satisfaction scores, and the ratio of operating expenses to revenue will provide insights into Astranas operational efficiency and competitiveness.
Astranas market capitalization is approximately $1.3 billion, indicating a mid-cap status. This size can provide a balance between the agility of smaller companies and the resources of larger ones, potentially allowing for strategic investments and expansion. The companys beta of 0.855 suggests relatively lower volatility compared to the broader market, which may appeal to risk-averse investors.
ASTH Stock Overview
| Market Cap in USD | 1,417m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2000-01-13 |
ASTH Stock Ratings
| Growth Rating | -50.9% |
| Fundamental | 59.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -51.5% |
| Analyst Rating | 4.50 of 5 |
ASTH Dividends
Currently no dividends paidASTH Growth Ratios
| Growth Correlation 3m | 58.4% |
| Growth Correlation 12m | -86.3% |
| Growth Correlation 5y | -1.8% |
| CAGR 5y | -8.81% |
| CAGR/Max DD 3y | -0.13 |
| CAGR/Mean DD 3y | -0.46 |
| Sharpe Ratio 12m | 0.05 |
| Alpha | -50.25 |
| Beta | 0.485 |
| Volatility | 52.71% |
| Current Volume | 205.4k |
| Average Volume 20d | 358k |
| Stop Loss | 28.3 (-5.1%) |
| Signal | -0.71 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (25.3m TTM) > 0 and > 6% of Revenue (6% = 145.1m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 9.50pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.28% (prev 16.29%; Δ -23.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 130.6m > Net Income 25.3m (YES >=105%, WARN >=100%) |
| Net Debt (29.4m) to EBITDA (112.1m) ratio: 0.26 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.5m) change vs 12m ago 3.11% (target <= -2.0% for YES) |
| Gross Margin 11.53% (prev 15.50%; Δ -3.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 227.0% (prev 127.1%; Δ 99.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.62 (EBITDA TTM 112.1m / Interest Expense TTM 31.6m) >= 6 (WARN >= 3) |
Altman Z'' 1.71
| (A) -0.20 = (Total Current Assets 15.9m - Total Current Liabilities 192.1m) / Total Assets 878.7m |
| (B) 0.34 = Retained Earnings (Balance) 302.2m / Total Assets 878.7m |
| (C) 0.08 = EBIT TTM 83.0m / Avg Total Assets 1.07b |
| (D) 1.31 = Book Value of Equity 302.2m / Total Liabilities 230.3m |
| Total Rating: 1.71 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 59.48
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 7.91% = 3.96 |
| 3. FCF Margin 4.89% = 1.22 |
| 4. Debt/Equity 0.65 = 2.30 |
| 5. Debt/Ebitda 3.74 = -2.45 |
| 6. ROIC - WACC -1.84% = -2.30 |
| 7. RoE 3.59% = 0.30 |
| 8. Rev. Trend 94.94% = 4.75 |
| 9. Rev. CAGR 30.19% = 2.50 |
| 10. EPS Trend -31.84% = -0.80 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ASTH shares?
Over the past week, the price has changed by +0.44%, over one month by +2.51%, over three months by +13.21% and over the past year by -42.27%.
Is Astrana Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ASTH is around 25.27 USD . This means that ASTH is currently overvalued and has a potential downside of -15.29%.
Is ASTH a buy, sell or hold?
- Strong Buy: 9
- Buy: 0
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ASTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.9 | 47.1% |
| Analysts Target Price | 43.9 | 47.1% |
| ValueRay Target Price | 27.6 | -7.4% |
Last update: 2025-09-05 04:33
ASTH Fundamental Data Overview
CCE Cash And Equivalents = 342.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 59.0385
P/E Forward = 23.0415
P/S = 0.5858
P/B = 1.9223
Beta = 0.855
Revenue TTM = 2.42b USD
EBIT TTM = 83.0m USD
EBITDA TTM = 112.1m USD
Long Term Debt = 401.1m USD (from longTermDebt, last quarter)
Short Term Debt = 17.8m USD (from shortTermDebt, last quarter)
Debt = 418.9m USD (Calculated: Short Term 17.8m + Long Term 401.1m)
Net Debt = 29.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.49b USD (1.42b + Debt 418.9m - CCE 342.1m)
Interest Coverage Ratio = 2.62 (Ebit TTM 83.0m / Interest Expense TTM 31.6m)
FCF Yield = 7.91% (FCF TTM 118.2m / Enterprise Value 1.49b)
FCF Margin = 4.89% (FCF TTM 118.2m / Revenue TTM 2.42b)
Net Margin = 1.04% (Net Income TTM 25.3m / Revenue TTM 2.42b)
Gross Margin = 11.53% ((Revenue TTM 2.42b - Cost of Revenue TTM 2.14b) / Revenue TTM)
Tobins Q-Ratio = 4.94 (Enterprise Value 1.49b / Book Value Of Equity 302.2m)
Interest Expense / Debt = 1.76% (Interest Expense 7.38m / Debt 418.9m)
Taxrate = 38.22% (30.9m / 80.8m)
NOPAT = 51.3m (EBIT 83.0m * (1 - 38.22%))
Current Ratio = 0.08 (Total Current Assets 15.9m / Total Current Liabilities 192.1m)
Debt / Equity = 0.65 (Debt 418.9m / last Quarter total Stockholder Equity 648.5m)
Debt / EBITDA = 3.74 (Net Debt 29.4m / EBITDA 112.1m)
Debt / FCF = 3.54 (Debt 418.9m / FCF TTM 118.2m)
Total Stockholder Equity = 702.8m (last 4 quarters mean)
RoA = 2.87% (Net Income 25.3m, Total Assets 878.7m )
RoE = 3.59% (Net Income TTM 25.3m / Total Stockholder Equity 702.8m)
RoCE = 7.52% (Ebit 83.0m / (Equity 702.8m + L.T.Debt 401.1m))
RoIC = 4.43% (NOPAT 51.3m / Invested Capital 1.16b)
WACC = 6.27% (E(1.42b)/V(1.84b) * Re(7.80%)) + (D(418.9m)/V(1.84b) * Rd(1.76%) * (1-Tc(0.38)))
Shares Correlation 3-Years: 87.88 | Cagr: 0.63%
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.02% ; FCFE base≈90.7m ; Y1≈89.1m ; Y5≈91.2m
Fair Price DCF = 35.06 (DCF Value 1.62b / Shares Outstanding 46.2m; 5y FCF grow -2.71% → 3.0% )
Revenue Correlation: 94.94 | Revenue CAGR: 30.19%
Rev Growth-of-Growth: 18.54
EPS Correlation: -31.84 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -117.0
Additional Sources for ASTH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle